Pharmacyte Biotech Inc (PMCB) 0.0605 $PMCB
PharmaCyte Biotech's CEO Explains How New Clinical Trial Design Changed the GMP Certification Process
Marketwired - Wed Apr 06, 8:20AM CDT
PharmaCyte Biotech (OTCQB: PMCB) expects to begin its clinical trial in advanced pancreatic cancer in 2016; however, locking down an exact date has been a challenge given the company dramatically changed course with its clinical trial design. While the new trial design offers PharmaCyte a much better shot at success with FDA and EMA approval, it has also been an exercise in patience for the company's leadership and its shareholders.
PharmaCyte Biotech Finalizes Design of Pancreatic Cancer Clinical Trial and Identifies Trial Sites under Consideration
GlobeNewswire - Thu Mar 31, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its live-cell encapsulation technology, Cell-in-a-Box, today announced the final design of its clinical trial for patients with advanced pancreatic cancer. The clinical trial design was developed with Translational Drug Development (TD2), America's premier oncology Contract Research Organization, as well as with renowned pancreatic cancer specialists consulting with PharmaCyte.
PharmaCyte Biotech Discusses Protection Strategy for Cancer and Diabetes Therapies
GlobeNewswire - Tue Mar 15, 8:48AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its live-cell encapsulation technology, Cell-in-a-Box, presents today another in a series of articles that will serve to educate the public on its live-cell encapsulation technology and its use in developing treatments for pancreatic cancer and diabetes. This educational piece addresses PharmaCyte's intellectual property (IP) and the strategy that PharmaCyte will employ to protect that property.
Valuing PharmaCyte Biotech's New Treatment Option for Pancreatic Cancer
ACCESSWIRE - Wed Mar 09, 8:00AM CST
BALTIMORE, MD / ACCESSWIRE / March 9, 2016 / The current gold standard of care for patients with advanced, inoperable pancreatic cancer is the combination therapy of Abraxane® + gemcitabine, which was approved by the U.S. Food and Drug Administration (FDA) in late 2013. Another treatment, which is not used as widely, is FOLFIRINOX, a four-drug combination therapy. These treatments offer varying degrees of efficacy but what happens to the patients when they no longer respond to these therapies? With limited options currently available, PharmaCyte Biotech (OTCQB - PMCB) is set to launch a new, mid-stage clinical trial in 2016 to specifically address what is clearly an unmet medical need and potentially increase the lifespan prospects for these late stage pancreatic cancer sufferers.
Tracking Volatility in Prices - Research on DMH International, Pharmacyte Biotech, Bear Creek Mining and Cielo
ACCESSWIRE - Wed Mar 09, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: DMH International Inc. (OTC: DMHI), Pharmacyte Biotech Inc. (OTC: PMCB), Bear Creek Mining Corp. (OTC: BCEKF) and Cielo SA. (OTC: CIOXY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
PharmaCyte Biotech Reports on Audit of Live-Cell Encapsulation Facility by Chamow & Associates
GlobeNewswire - Thu Mar 03, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its live-cell encapsulation technology, Cell-in-a-Box, reported today on Chamow & Associates' (Chamow) audit of Austrianova's live-cell encapsulation facility in Bangkok, Thailand, and the progress being made to establish that the facility will be cGMP compliant. Chamow is a biopharmaceutical consulting firm with industry experts that specialize in the inspection of facilities for current Good Manufacturing Practices (cGMP) compliance and in the preparation of the Chemistry, Manufacturing and Controls (CMC) section of an Investigational New Drug application (IND). The Austrianova facility will employ the Cell-in-a-Box technology to produce the microcapsules that, together with low doses of the anticancer prodrug ifosfamide, make up PharmaCyte's therapy for pancreatic cancer.
Stonegate Capital Partners Publishes Research Report on PharmaCyte Biotech
GlobeNewswire - Wed Feb 10, 8:32AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Stonegate Capital Partners (Stonegate), a privately held corporate advisory firm based in Dallas, Texas, with offices in New York and Boston, issued a Research Report featuring PharmaCyte Biotech. The report can be viewed at http://stonegateinc.com/reports/Pharma_Feb_2016.pdf
Where are the Traders Headed - Analyst Notes on CD International Enterprises, Valley High Mining, Pharmacyte Biotech and Bombardier
ACCESSWIRE - Tue Feb 02, 6:33AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CD International Enterprises Inc. (OTC: CDII), Valley High Mining Co. (OTC: VHMC), Pharmacyte Biotech Inc. (OTC: PMCB) and Bombardier Inc. (OTC: BDRBF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Trading Ahead of Upcoming Developments -- New Research on Trans-Pacific Aerospace Company, Pharmacyte Biotech, First Mining Finance, and Accretive Health
ACCESSWIRE - Mon Feb 01, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trans-Pacific Aerospace Company Inc. (OTC: TPAC), Pharmacyte Biotech Inc. (OTC: PMCB), First Mining Finance Corp. (OTC: FFMGF) and Accretive Health Inc. (OTC: ACHI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Presidential Elections Put Cannabis & Cannabis Stocks To Watch, Center Stage In 2016
ACCESSWIRE - Thu Jan 28, 6:44AM CST
CORAL GABLES, FL / ACCESSWIRE / January 28, 2016 / There's no debating the wild ride the marijuana industry has had since legalization for recreational use went live in 2014. Now two years later we are faced with a very critical time in the country's history not only because many other states are adopting legalization initiatives but also because this is an election year.
PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
GlobeNewswire - Mon Jan 25, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development (TD2) at TD2's facilities in Scottsdale, Arizona. The meeting was held to discuss a number of aspects related to PharmaCyte's upcoming clinical trial in pancreatic cancer and the structure of the Investigational New Drug Application (IND) that must be submitted to the FDA and found acceptable before the clinical trial can begin. PharmaCyte has contracted with TD2 to be the lead Contract Research Organization (CRO) to prepare for and conduct PharmaCyte's clinical trial in pancreatic cancer.
The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
ACCESSWIRE - Thu Jan 21, 8:12AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience Inc. (OTC: SCIE), Pharmacyte Biotech Inc. (OTC: PMCB), Silvercorp Metals Inc. (OTC: SVMLF) and Aytu BioScience Inc. (OTC: AYTU). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
PharmaCyte Biotech Introduces Cell-in-a-Box as a Novel Treatment for Pancreatic Cancer and Potential Cure for Type 1 Diabetes
GlobeNewswire - Tue Jan 19, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, released today another in a series of educational articles that will serve to educate the public on its live-cell encapsulation technology and its pancreatic cancer and diabetes treatments using that technology. This educational piece titled, Cellular Microencapsulation: Cell Encapsulation for Drug Delivery & Disease Treatment, is authored by PharmaCyte's Chief Operating Officer, Dr. Gerald W. Crabtree.
PharmaCyte Biotech Raises Additional $1 Million for Pancreatic Cancer Clinical Trial
GlobeNewswire - Thu Jan 14, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that the Company raised an additional $1 million. A Form 8-K was filed yesterday with the SEC providing the details of the capital raise. PharmaCyte has shown repeatedly the ability to raise the funds necessary to get into a pancreatic cancer clinical trial and to continue its work in both pancreatic cancer and diabetes.
Perception, Opportunity in Volatility - Free Research on Ambient Water, Pharmacyte Biotech, Soligenix and Epsilon Energy
ACCESSWIRE - Thu Jan 14, 7:03AM CST
NEW YORK, NY / ACCESSWIRE / January 14, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Ambient Water Corp. (OTC: AWGI), Pharmacyte Biotech Inc. (OTC: PMCB), Soligenix Inc. (OTC: SNGX) and Epsilon Energy Ltd. (OTC: EPSEF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
PharmaCyte Biotech to Attend J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 07, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the Company's Chief Executive Officer, Kenneth L. Waggoner, will attend the 34 Annual J.P. Morgan Healthcare Conference in San Francisco, California, from January 10-15, 2016. PharmaCyte has a full schedule of meetings in which the CEO will present and update PharmaCyte's platform technology in the treatment of pancreatic cancer and diabetes to potential institutional investors, pharmaceutical companies, and the life science media.
JPM: 58.81 (+0.45)
PharmaCyte Biotech Outlines 2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial
GlobeNewswire - Mon Jan 04, 7:45AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the Company's 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of PharmaCyte Biotech, Inc. (OTCMKTS: PMCB)
PR Newswire - Thu Dec 31, 12:01PM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of PharmaCyte Biotech Inc., ("PharmaCyte" or "the Company"
(OTCMKTS: PMCB). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
GlobeNewswire - Wed Dec 30, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today a shareholder update on PharmaCyte's pancreatic cancer and diabetes programs.
PharmaCyte Biotech Releases New Video Highlighting Diabetes Treatment Development Program
GlobeNewswire - Tue Dec 15, 9:24AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that it has released a new video that highlights PharmaCyte's diabetes treatment development program. PharmaCyte invited Stock Market Media to sit in on its 2nd Annual International Diabetes Consortium in Vienna, Austria, to document PharmaCyte's story related to the development of its treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes.
PharmaCyte Biotech's CEO Explains How New Clinical Trial Design Changed the GMP Certification Process
Marketwired - Wed Apr 06, 8:20AM CDT
PharmaCyte Biotech (OTCQB: PMCB) expects to begin its clinical trial in advanced pancreatic cancer in 2016; however, locking down an exact date has been a challenge given the company dramatically changed course with its clinical trial design. While the new trial design offers PharmaCyte a much better shot at success with FDA and EMA approval, it has also been an exercise in patience for the company's leadership and its shareholders.
PharmaCyte Biotech Finalizes Design of Pancreatic Cancer Clinical Trial and Identifies Trial Sites under Consideration
GlobeNewswire - Thu Mar 31, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its live-cell encapsulation technology, Cell-in-a-Box, today announced the final design of its clinical trial for patients with advanced pancreatic cancer. The clinical trial design was developed with Translational Drug Development (TD2), America's premier oncology Contract Research Organization, as well as with renowned pancreatic cancer specialists consulting with PharmaCyte.
PharmaCyte Biotech Discusses Protection Strategy for Cancer and Diabetes Therapies
GlobeNewswire - Tue Mar 15, 8:48AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its live-cell encapsulation technology, Cell-in-a-Box, presents today another in a series of articles that will serve to educate the public on its live-cell encapsulation technology and its use in developing treatments for pancreatic cancer and diabetes. This educational piece addresses PharmaCyte's intellectual property (IP) and the strategy that PharmaCyte will employ to protect that property. Valuing PharmaCyte Biotech's New Treatment Option for Pancreatic Cancer
ACCESSWIRE - Wed Mar 09, 8:00AM CST
BALTIMORE, MD / ACCESSWIRE / March 9, 2016 / The current gold standard of care for patients with advanced, inoperable pancreatic cancer is the combination therapy of Abraxane® + gemcitabine, which was approved by the U.S. Food and Drug Administration (FDA) in late 2013. Another treatment, which is not used as widely, is FOLFIRINOX, a four-drug combination therapy. These treatments offer varying degrees of efficacy but what happens to the patients when they no longer respond to these therapies? With limited options currently available, PharmaCyte Biotech (OTCQB - PMCB) is set to launch a new, mid-stage clinical trial in 2016 to specifically address what is clearly an unmet medical need and potentially increase the lifespan prospects for these late stage pancreatic cancer sufferers.
Tracking Volatility in Prices - Research on DMH International, Pharmacyte Biotech, Bear Creek Mining and Cielo
ACCESSWIRE - Wed Mar 09, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: DMH International Inc. (OTC: DMHI), Pharmacyte Biotech Inc. (OTC: PMCB), Bear Creek Mining Corp. (OTC: BCEKF) and Cielo SA. (OTC: CIOXY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
PharmaCyte Biotech Reports on Audit of Live-Cell Encapsulation Facility by Chamow & Associates
GlobeNewswire - Thu Mar 03, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its live-cell encapsulation technology, Cell-in-a-Box, reported today on Chamow & Associates' (Chamow) audit of Austrianova's live-cell encapsulation facility in Bangkok, Thailand, and the progress being made to establish that the facility will be cGMP compliant. Chamow is a biopharmaceutical consulting firm with industry experts that specialize in the inspection of facilities for current Good Manufacturing Practices (cGMP) compliance and in the preparation of the Chemistry, Manufacturing and Controls (CMC) section of an Investigational New Drug application (IND). The Austrianova facility will employ the Cell-in-a-Box technology to produce the microcapsules that, together with low doses of the anticancer prodrug ifosfamide, make up PharmaCyte's therapy for pancreatic cancer. Stonegate Capital Partners Publishes Research Report on PharmaCyte Biotech
GlobeNewswire - Wed Feb 10, 8:32AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Stonegate Capital Partners (Stonegate), a privately held corporate advisory firm based in Dallas, Texas, with offices in New York and Boston, issued a Research Report featuring PharmaCyte Biotech. The report can be viewed at http://stonegateinc.com/reports/Pharma_Feb_2016.pdf Where are the Traders Headed - Analyst Notes on CD International Enterprises, Valley High Mining, Pharmacyte Biotech and Bombardier
ACCESSWIRE - Tue Feb 02, 6:33AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CD International Enterprises Inc. (OTC: CDII), Valley High Mining Co. (OTC: VHMC), Pharmacyte Biotech Inc. (OTC: PMCB) and Bombardier Inc. (OTC: BDRBF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Trading Ahead of Upcoming Developments -- New Research on Trans-Pacific Aerospace Company, Pharmacyte Biotech, First Mining Finance, and Accretive Health
ACCESSWIRE - Mon Feb 01, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trans-Pacific Aerospace Company Inc. (OTC: TPAC), Pharmacyte Biotech Inc. (OTC: PMCB), First Mining Finance Corp. (OTC: FFMGF) and Accretive Health Inc. (OTC: ACHI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Presidential Elections Put Cannabis & Cannabis Stocks To Watch, Center Stage In 2016
ACCESSWIRE - Thu Jan 28, 6:44AM CST
CORAL GABLES, FL / ACCESSWIRE / January 28, 2016 / There's no debating the wild ride the marijuana industry has had since legalization for recreational use went live in 2014. Now two years later we are faced with a very critical time in the country's history not only because many other states are adopting legalization initiatives but also because this is an election year.
PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
GlobeNewswire - Mon Jan 25, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development (TD2) at TD2's facilities in Scottsdale, Arizona. The meeting was held to discuss a number of aspects related to PharmaCyte's upcoming clinical trial in pancreatic cancer and the structure of the Investigational New Drug Application (IND) that must be submitted to the FDA and found acceptable before the clinical trial can begin. PharmaCyte has contracted with TD2 to be the lead Contract Research Organization (CRO) to prepare for and conduct PharmaCyte's clinical trial in pancreatic cancer. The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
ACCESSWIRE - Thu Jan 21, 8:12AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience Inc. (OTC: SCIE), Pharmacyte Biotech Inc. (OTC: PMCB), Silvercorp Metals Inc. (OTC: SVMLF) and Aytu BioScience Inc. (OTC: AYTU). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
PharmaCyte Biotech Introduces Cell-in-a-Box as a Novel Treatment for Pancreatic Cancer and Potential Cure for Type 1 Diabetes
GlobeNewswire - Tue Jan 19, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, released today another in a series of educational articles that will serve to educate the public on its live-cell encapsulation technology and its pancreatic cancer and diabetes treatments using that technology. This educational piece titled, Cellular Microencapsulation: Cell Encapsulation for Drug Delivery & Disease Treatment, is authored by PharmaCyte's Chief Operating Officer, Dr. Gerald W. Crabtree. PharmaCyte Biotech Raises Additional $1 Million for Pancreatic Cancer Clinical Trial
GlobeNewswire - Thu Jan 14, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that the Company raised an additional $1 million. A Form 8-K was filed yesterday with the SEC providing the details of the capital raise. PharmaCyte has shown repeatedly the ability to raise the funds necessary to get into a pancreatic cancer clinical trial and to continue its work in both pancreatic cancer and diabetes. Perception, Opportunity in Volatility - Free Research on Ambient Water, Pharmacyte Biotech, Soligenix and Epsilon Energy
ACCESSWIRE - Thu Jan 14, 7:03AM CST
NEW YORK, NY / ACCESSWIRE / January 14, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Ambient Water Corp. (OTC: AWGI), Pharmacyte Biotech Inc. (OTC: PMCB), Soligenix Inc. (OTC: SNGX) and Epsilon Energy Ltd. (OTC: EPSEF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
PharmaCyte Biotech to Attend J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 07, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the Company's Chief Executive Officer, Kenneth L. Waggoner, will attend the 34 Annual J.P. Morgan Healthcare Conference in San Francisco, California, from January 10-15, 2016. PharmaCyte has a full schedule of meetings in which the CEO will present and update PharmaCyte's platform technology in the treatment of pancreatic cancer and diabetes to potential institutional investors, pharmaceutical companies, and the life science media. JPM: 58.81 (+0.45)
PharmaCyte Biotech Outlines 2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial
GlobeNewswire - Mon Jan 04, 7:45AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the Company's 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of PharmaCyte Biotech, Inc. (OTCMKTS: PMCB)
PR Newswire - Thu Dec 31, 12:01PM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of PharmaCyte Biotech Inc., ("PharmaCyte" or "the Company"
(OTCMKTS: PMCB). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
GlobeNewswire - Wed Dec 30, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today a shareholder update on PharmaCyte's pancreatic cancer and diabetes programs. PharmaCyte Biotech Releases New Video Highlighting Diabetes Treatment Development Program
GlobeNewswire - Tue Dec 15, 9:24AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that it has released a new video that highlights PharmaCyte's diabetes treatment development program. PharmaCyte invited Stock Market Media to sit in on its 2nd Annual International Diabetes Consortium in Vienna, Austria, to document PharmaCyte's story related to the development of its treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. 
